Psychiatry Research
Volume 179, Issue 2 , Pages 147-150 , 30 September 2010

Analysis of association between the catechol-O-methyltransferase (COMT) gene and negative symptoms in chronic schizophrenia

  • Yan Wang
    • ,
  • Yue Fang
    • ,
  • Yan Shen
    • ,
  • Qi Xu

      Affiliations

    • Corresponding Author InformationCorresponding author. National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Science, Tsinghua University, Beijing 100005, China. Tel.: +86 10 65296432; fax: +86 10 65263392.

Received 28 July 2008 ,Revised 7 January 2009 ,Accepted 19 March 2009.

References 

  1. Ananth J, Djenderdjian A, Shamasunder P, Costa J, Herrera J, Sramek J. Negative symptoms: psychopathological models. Journal of Psychiatry and Neuroscience. 1991;16:12–18
  2. Andreasen NC, Rezai K, Alliger R, Swayze VW, Flaum M, Kirchner P, et al. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Archives of General Psychiatry. 1992;49:943–958
  3. Bertolino A, Caforio G, Blasi G, De Candia M, Latorre V, Petruzzella V, et al. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. American Journal of Psychiatry. 2004;161:1798–1805
  4. Bilder RM, Volavka J, Czobor P, Malhotra AK, Kennedy JL, Ni X, et al. Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biological Psychiatry. 2002;52:701–707
  5. Boudikova B, Szumlanski C, Maidak B, Weinshilboum R. Human liver catechol-O-methyltransferase pharmacogenetics. Clinical Pharmacology and Therapeutics. 1990;48:381–389
  6. Bulmer M. Coevolution of codon usage and transfer RNA abundance. Nature. 1987;325:728–730
  7. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. American Journal of Psychiatry. 1991;148:1474–1486
  8. Dudbridge F. Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Human Heredity. 2008;66:87–98
  9. Dworkin RH, Lenzenweger MF. Symptoms and the genetics of schizophrenia: implications for diagnosis. American Journal of Psychiatry. 1984;141:1541–1546
  10. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 2001;98:6917–6922
  11. Ehlis AC, Reif A, Herrmann MJ, Lesch KP, Fallgatter AJ. Impact of catechol-O-methyltransferase on prefrontal brain functioning in schizophrenia spectrum disorders. Neuropsychopharmacology. 2007;32:162–170
  12. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Molecular Biology and Evolution. 1995;12:921–927
  13. Herken H, Erdal ME. Catechol-O-methyltransferase gene polymorphism in schizophrenia: evidence for association between symptomatology and prognosis. Psychiatric Genetics. 2001;11:105–109
  14. Malaspina D, Goetz RR, Yale S, Berman A, Friedman JH, Tremeau F, et al. Relation of familial schizophrenia to negative symptoms but not to the deficit syndrome. American Journal of Psychiatry. 2000;157:994–1003
  15. McClay JL, Fanous A, van den Oord EJ, Webb BT, Walsh D, O'Neill FA, et al. Catechol-O-methyltransferase and the clinical features of psychosis. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 2006;141B:935–938
  16. Molero P, Ortuno F, Zalacain M, Patino-Garcia A. Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment. Pharmacogenomics Journal. 2007;7:418–426
  17. Nackley AG, Shabalina SA, Tchivileva IE, Satterfield K, Korchynskyi O, Makarov SS, et al. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science. 2006;314:1930–1933
  18. Riehemann S, Volz HP, Stutzer P, Smesny S, Gaser C, Sauer H. Hypofrontality in neuroleptic-naive schizophrenic patients during the Wisconsin Card Sorting Test—a fMRI study. European Archives of Psychiatry and Clinical Neuroscience. 2001;251:66–71
  19. Roth RM, Flashman LA, Saykin AJ, McAllister TW, Vidaver R. Apathy in schizophrenia: reduced frontal lobe volume and neuropsychological deficits. American Journal of Psychiatry. 2004;161:157–159
  20. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Medicine. 2005;2:e141
  21. Schurhoff F, Szoke A, Chevalier F, Roy I, Meary A, Bellivier F, et al. Schizotypal dimensions: an intermediate phenotype associated with the COMT high activity allele. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 2007;144B:64–68
  22. Sesack SR, Hawrylak VA, Matus C, Guido MA, Levey AI. Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. Journal of Neuroscience. 1998;18:2697–2708
  23. Sharafi M. Comparison of classical and clozapine treatment on schizophrenia using Positive and Negative Syndrome Scale of Schizophrenia (PANSS) and SPECT imaging. International Journal of Medical Sciences. 2005;2:79–86
  24. Smyrnis N, Avramopoulos D, Evdokimidis I, Stefanis CN, Tsekou H, Stefanis NC. Effect of schizotypy on cognitive performance and its tuning by COMT val158 met genotype variations in a large population of young men. Biological Psychiatry. 2007;61:845–853
  25. Stratta P, Daneluzzo E, Bustini M, Prosperini P, Rossi A. Processing of context information in schizophrenia: relation to clinical symptoms and WCST performance. Schizophrenia Research. 2000;44:57–67
  26. Strous RD, Lapidus R, Viglin D, Kotler M, Lachman HM. Analysis of an association between the COMT polymorphism and clinical symptomatology in schizophrenia. Neuroscience Letters. 2006;393:170–173
  27. Tao R, Wei J, Guo Y, Yu Y, Xu Q, Shi J, et al. The PLA2G4A gene and negative symptoms in a Chinese population. Schizophrenia Research. 2006;86:326–328
  28. van der Gaag M, Hoffman T, Remijsen M, Hijman R, de Haan L, van Meijel B, et al. The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model. Schizophrenia Research. 2006;85:280–287
  29. Weickert TW, Goldberg TE, Mishara A, Apud JA, Kolachana BS, Egan MF, et al. Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biological Psychiatry. 2004;56:677–682

PII: S0165-1781(09)00130-9

doi: 10.1016/j.psychres.2009.03.029

Psychiatry Research
Volume 179, Issue 2 , Pages 147-150 , 30 September 2010

Article Tools

* Image Usage & Resolution